MedTrace Logo

Levetiracetam for the Treatment of Alcohol Dependence and Anxiety

NCT00141115 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2019-04-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if levetiracetam is effective in treating alcohol dependence in patients with anxiety symptoms. The researchers hypothesize that individuals are unable to reduce or discontinue alcohol use because of significant anxiety, mood, and sleep disturbance symptoms that accompany reduction in alcohol use.

Conditions

  • Alcoholism
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Social Phobia
  • Anxiety Disorders

Interventions

DRUG

levetiracetam

Levetiracetam 1500 mg BID

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Frances R Levin, MD · New York State Psychiatric Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00141115 on ClinicalTrials.gov